RIGEL PHARMACEUTICALS INC's ticker is RIGL and the CUSIP is 766559603. A total of 122 filers reported holding RIGEL PHARMACEUTICALS INC in Q2 2015. The put-call ratio across all filers is 3.13 and the average weighting 0.1%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q4 2016 | $891,000 | -35.2% | 374,383 | -0.2% | 0.00% | -50.0% |
Q3 2016 | $1,376,000 | +78.0% | 375,016 | +8.2% | 0.00% | +100.0% |
Q2 2016 | $773,000 | +17.5% | 346,722 | +9.5% | 0.00% | 0.0% |
Q1 2016 | $658,000 | -32.2% | 316,511 | -1.1% | 0.00% | 0.0% |
Q4 2015 | $970,000 | +23.9% | 320,112 | +1.0% | 0.00% | 0.0% |
Q3 2015 | $783,000 | -24.6% | 316,909 | -2.1% | 0.00% | 0.0% |
Q2 2015 | $1,039,000 | +0.8% | 323,610 | +12.1% | 0.00% | 0.0% |
Q1 2015 | $1,031,000 | +56.4% | 288,736 | -0.5% | 0.00% | 0.0% |
Q4 2014 | $659,000 | -5.3% | 290,262 | -19.1% | 0.00% | 0.0% |
Q3 2014 | $696,000 | -47.0% | 358,627 | -0.8% | 0.00% | -50.0% |
Q2 2014 | $1,312,000 | +13.8% | 361,558 | +21.7% | 0.00% | 0.0% |
Q1 2014 | $1,153,000 | +35.6% | 297,076 | -0.4% | 0.00% | +100.0% |
Q4 2013 | $850,000 | -21.9% | 298,344 | -1.9% | 0.00% | -50.0% |
Q3 2013 | $1,089,000 | +7.9% | 304,203 | +0.7% | 0.00% | 0.0% |
Q2 2013 | $1,009,000 | – | 301,995 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
CM Management, LLC | 1,500,000 | $1,620,000 | 1.72% |
Soleus Capital Management, L.P. | 14,803,015 | $15,987,256 | 1.48% |
ARMISTICE CAPITAL, LLC | 17,136,000 | $18,506,880 | 0.28% |
SPHERA FUNDS MANAGEMENT LTD. | 1,228,126 | $1,326,376 | 0.24% |
GSA CAPITAL PARTNERS LLP | 971,441 | $1,049 | 0.09% |
NJ State Employees Deferred Compensation Plan | 200,000 | $216,000 | 0.03% |
Providence Wealth Advisors, LLC | 27,500 | $29,013 | 0.03% |
XTX Topco Ltd | 164,238 | $177,377 | 0.03% |
JACOBS LEVY EQUITY MANAGEMENT, INC | 3,369,076 | $3,638,602 | 0.02% |
OCONNOR, A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS (LLC) | 1,151,765 | $1,243,906 | 0.02% |